Accessibility navigation


Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib

Bye, A. P. ORCID: https://orcid.org/0000-0002-2061-2253, Kriek, N., Sage, T., Rawlings, S. J., Prodger, C., Kesavan, M., Lees, C., Booth, S., Cowen, L. G., Shefferd, K., Desborough, M. J., Gibbins, J. M. ORCID: https://orcid.org/0000-0002-0372-5352 and Eyre, T. A. (2023) Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib. Haematologica, 108 (5). ISSN 1592-8721

[img]
Preview
Text (Open Access) - Published Version
· Available under License Creative Commons Attribution.
· Please see our End User Agreement before downloading.

885kB
[img] Text - Accepted Version
· Restricted to Repository staff only

677kB

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.3324/haematol.2022.281402


Item Type:Article
Refereed:Yes
Divisions:Interdisciplinary centres and themes > Institute for Cardiovascular and Metabolic Research (ICMR)
Life Sciences > School of Biological Sciences > Biomedical Sciences
Interdisciplinary centres and themes > Health Innovation Partnership (HIP)
ID Code:110390
Uncontrolled Keywords:Haemostasis, platelets, bleeding, Bruton tyrosine kinase, chronic lymphocytic leukaemia.
Publisher:Ferrata Storti Foundation

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation